Evidence map›Paper›PMID 38716645›Full record

SynthesisCancer medicine2024

Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta-analysis.

Danzhu Wu, Liyuan Yang, Yu Yan, Zhengchen Jiang, Yinglong Liu, Peng Dong, Yajuan Lv, Siqin Zhou, Yiyang Qiu, Xinshuang Yu

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Danzhu WuClinical Medical College of Jining Medical University, Jining, Shandong Province, China.
Liyuan YangShandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Yu YanShandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Zhengchen JiangDepartment of General Surgery, Shandong Provincial Qianfoshan Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Yinglong LiuShandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Peng DongDepartment of Oncology, The Second Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Taian, Jinan, Shandong, China.
Yajuan LvDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, National Key Laboratory of Advanced Drug Delivery and Release Systems, Jinan, Shandong, China.
Siqin ZhouMedical College, Wuhan University of Science and Technology, Wuhan, China.
Yiyang QiuSchool of Nursing, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Xinshuang YuDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, National Key Laboratory of Advanced Drug Delivery and Release Systems, Jinan, Shandong, China.ORCID 0000-0001-9095-3435

Funding

Bethune-Cancer Radiotherapy Translational Medicine Research Fund flzh202113Clinical Research Fund of Shandong Medical Association-Qilu Special Project YXH2022ZX02199
6 · The paper itself

Abstract

backgroundIn recent years, neoadjuvant immunotherapy (NAIT) has developed rapidly in patients with gastroesophageal junction cancer (GEJC). The suggested neoadjuvant treatment regimens for patients with GEJC may vary in light of the efficacy and safety results.

methodsA search of the Cochrane Library, PubMed, Embase, and Web of Science was completed to locate studies examining the safety and effectiveness of NAIT for resectable GEJC. We analyzed the effect sizes (ES) and 95% confidence intervals (CI) in addition to subgroups and heterogeneity. Meta-analyses were performed using Stata BE17 software.

resultsFor these meta-analyses, 753 patients were chosen from 21 studies. The effectiveness of NAIT was assessed using the pathological complete response (pCR), major pathological response (MPR), and nodal downstage to ypN0 rate. The MPR, pCR, and nodal downstage to ypN0 rate values in NAIT were noticeably higher (MPR: ES = 0.45; 95% CI: 0.36-0.54; pCR: ES = 0.26; 95% CI: 0.21-0.32; nodal downstage to ypN0 rate: ES = 0.60; 95% CI: 0.48-0.72) than those of neoadjuvant chemotherapy (nCT) or neoadjuvant chemoradiotherapy (nCRT) (MPR < 30%; pCR: ES = 3%-17%; nodal downstage to ypN0 rate: ES = 21%-29%). Safety was assessed using the treatment-related adverse events (trAEs) incidence rate, surgical delay rate, surgical complications incidence rate, and surgical resection rate. In conclusion, the incidence of trAEs, incidence of surgical complications, and surgical delay rate had ES values of 0.66, 0.48, and 0.09, respectively. These rates were comparable to those from nCT or nCRT (95% CI: 0.60-0.70; 0.15-0.51; and 0, respectively). The reported resection rates of 85%-95% with nCT or nCRT were comparable to the mean surgical resection rate of 90%.

conclusionNAIT is an effective treatment for resectable GEJC; additionally, the level of NAIT toxicity is acceptable. The long-term effects of NAIT require further study.

Indexed as

Esophageal NeoplasmsEsophagogastric JunctionImmunotherapyNeoadjuvant TherapyStomach NeoplasmsHumansTreatment Outcomecancergastroesophageal junctionmeta‐analysisneoadjuvant immunotherapy

Identifiers

PMID38716645
PMCPMC11077431

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.